Alimentary Pharmacology & Therapeutics最新文献

{"title":"Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply","authors":"Chachrit Khunsriraksakul, Olivia Ziegler, Dajiang Liu, Audrey S. Kulaylat, Matthew D. Coates","doi":"10.1111/apt.70186","DOIUrl":"https://doi.org/10.1111/apt.70186","url":null,"abstract":"<p>We appreciate the opportunity to respond to the comments submitted by Mao et al. [<span>1</span>] relating to our article [<span>2</span>]. They provided thoughtful commentary about the strengths and weaknesses of our study, and we agree with several concerns and recommendations that they shared. For example, they highlighted the potential limitations of relying upon ICD-10 codes to assess the abdominal pain status of each patient, including the lack of ‘granularity’ in data related to pain severity, frequency and chronicity. Mao et al. also pointed out that this investigation was not able to necessarily discern between individuals with quiescent or active inflammatory bowel disease (IBD), and appropriately concluded that this made it difficult to determine why patients in this study were receiving antispasmodics, and whether particular sub-cohorts (e.g., those with quiescent IBD and concomitant irritable bowel syndrome (IBS)) would demonstrate better outcomes after receiving these therapies. Additionally, they noted that almost two thirds of the patients included in our study did not report a racial identity. They also mentioned that there was a lack of information about participant socioeconomic status and education level. We appreciate all of these criticisms, and agree that they are all worthy of consideration. Indeed, as stated in our Discussion, there are important issues directly related to the use of retrospectively abstracted claims data that limit the inferences that can be made about this topic. In our Conclusions, we advocated for follow-on prospective studies to help address the limitations noted above.</p>\u0000<p>Despite these concerns, we believe this study is important for several reasons. It is the first large-scale study investigating the clinical impact of antispasmodics in IBD. While there were potential limitations related to data type and quality, the database utilised has served as one of the largest and most comprehensive sources of information in the world for population-based studies and includes data from a wide variety of healthcare centres located around the world [<span>3</span>]. Thus, it is likely that the associated study cohort provided a ‘real-world’ assessment of antispasmodic provision and its impact in IBD. As stated above, Mao et al. suggested that antispasmodic use is more likely to be successful in patients with quiescent IBD who exhibit visceral hypersensitivity or IBS. It is important to note that there is no definitive evidence in IBD to support this statement. This is, in fact, one of the reasons we undertook this study. However, even if that statement is eventually determined to be accurate, previous investigations demonstrate that, when healthcare providers believe that patients with IBD are in remission, many harbour unrecognised inflammation and other factors (unrelated to IBS or visceral hypersensitivity) that may contribute to abdominal pain [<span>4, 5</span>]. Thus, identifying the optimal targe","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"3 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143920814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes Mellitus in Patients With Autoimmune Hepatitis: Frequency, Risk Factors and Effect on Outcome","authors":"Sarah Flatley, Selena Dixon, Eleanor Pilsworth, Asha Dube, Barbara Hoeroldt, Laura Harrison, Dermot Gleeson","doi":"10.1111/apt.70188","DOIUrl":"https://doi.org/10.1111/apt.70188","url":null,"abstract":"BackgroundTreatment for autoimmune hepatitis (AIH) includes corticosteroids, which are associated with the development of diabetes mellitus (DM). Reported new‐onset DM rates in patients with AIH have varied, and predisposing factors and prognostic implications are inadequately characterised.AimTo identify the frequency and predisposing factors for DM in AIH and its association with disease progression and mortality.MethodsRetrospective/prospective single‐centre study of 494 patients with AIH presenting 1987–2023, 466 receiving corticosteroids (454 prednisolone, 12 budesonide) and followed for (median (range) 9 (0–36) years).ResultsForty‐seven patients (10%) already had DM at AIH diagnosis. New‐onset DM subsequently developed in another 59 (13%). In those receiving prednisolone, new‐onset DM incidence was 8% ± 1% after 1 year and 14% ± 2% after 10 years (14‐ and 3‐fold higher than expected population rate), and was independently associated with older age, non‐Caucasian ethnicity, higher initial prednisolone dose, higher BMI at diagnosis and more weight gain after 2 years of follow‐up. New‐onset DM usually persisted despite stopping prednisolone.New‐onset DM and DM at any time were independently associated with all‐cause death/transplantation rate, along with previously established risk factors (older age, cirrhosis, lower ALT at diagnosis and failure of early ALT normalisation). New‐onset DM and DM at any time were also independently associated with cirrhosis development. Similar associations of new‐onset DM and DM at any time with liver‐related death/transplantation were significant on univariate but not multivariate analysis.ConclusionNew‐onset DM occurred in 13% of patients with AIH, was related to older age, non‐Caucasian ethnicity, higher prednisolone dose, higher BMI at diagnosis and weight gain; and was an independent predictor of all‐cause death/transplantation and of cirrhosis development, underlining the need to minimise steroid burden in AIH.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"20 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143920319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter: Is Enteric Neuropathy Absent in Hypermobility Spectrum Disorders/Hypermobile Ehlers-Danlos Syndrome?","authors":"Caitlin Green, Anne Maitland, Steven A. Kautz, Russell Norris, Sunil Patel, Amol Sharma","doi":"10.1111/apt.70142","DOIUrl":"10.1111/apt.70142","url":null,"abstract":"<p>We commend Sweerts et al. for their largest-to-date investigation using antroduodenal manometry (ADM) in 50 patients with hypermobility spectrum disorders (HSD) and hypermobile Ehler-Danlos Syndrome (hEDS) compared to 189 non-HSD/hEDS patients [<span>1</span>]. ADM, a labour-intensive and technically challenging procedure, comes the closest to the gold standard of histopathological evaluation of full-thickness tissue specimens for diagnosing enteric myopathy or neuropathy. Key findings of the study were similar rates of antroduodenal dysmotility and delayed gastric emptying, but less enteric dysmotility in HSD/hEDS patients. As discussed, malnutrition was highly prevalent with 76% of HSD/hEDS patients receiving enteral (62%) or parenteral (13%) support. In contrast, the non-HSD/hEDS comparator group had nearly double the proportion of patients not receiving enteral or parenteral nutrition, suggesting differences in meal tolerability. The ADM protocol employed in this study only allowed a ‘one shot’ assessment of enteric function via a single meal. While logistical and technical challenges exist, 24-h recordings present more opportunities to detect enteric motility between meals, in response to multiple meals, in response to a non-meal stimulus through promotility agents, and diurnal variation [<span>2</span>]. The conclusion of a lower prevalence of enteric dysmotility in the HSD/hEDS cohort based on a single meal challenge in patients with poor meal tolerability during ADM may be premature.</p><p>Delayed gastric emptying was present in 85% of the HSD/hEDS cohort. While validated symptom scores for gastroparesis and/or functional dyspepsia were not captured, the corresponding predominant symptom was a cardinal gastroparesis symptom in most patients (nausea/vomiting > 50% and abdominal pain and excessive fullness ~25% of HSD/hEDS group), projected to meet diagnostic criteria for gastroparesis. In gastroparesis overall (i.e., not limited to HSD/hEDS), constipation remains understudied and poorly understood from a pathophysiological standpoint. Fifty-eight percent of patients with gastroparesis have moderate to very severe constipation, and the severity of constipation symptoms correlates with the severity of gastroparesis symptoms [<span>3</span>]. Based on our clinical observations and the lack of use of a prospective stool diary in this study, constipation was probably underreported by HSD/hEDS participants. Underlying rectal evacuation disorders are key drivers of pathophysiology in severe constipation and are present in 60%–75% of patients with HSD/hEDS undergoing anorectal manometry [<span>4, 5</span>].</p><p>While the prevalence of enteric dysmotility or neuropathy in HSD/hEDS remains unclear, more than half of HSD/hEDS patients have associated postural orthostatic tachycardia syndrome and dysautonomia [<span>6</span>]. Transauricular vagal nerve stimulation targeting dysautonomia is promising for functional dyspepsia, also highly preva","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"61 11","pages":"1843-1844"},"PeriodicalIF":6.6,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.70142","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143915079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter: Is Enteric Neuropathy Absent in Hypermobility Spectrum Disorders/Hypermobile Ehler–Danlos Syndrome? Authors' Reply","authors":"Kim W. E. Sweerts,&nbsp;Zlatan Mujagic,&nbsp;Daniel Keszthelyi,&nbsp;José M. Conchillo","doi":"10.1111/apt.70157","DOIUrl":"10.1111/apt.70157","url":null,"abstract":"<p>We appreciate the interest and comments of Dr. Green and colleagues on our article about antroduodenal motility in patients with hypermobility spectrum disorders/hypermobile Ehlers–Danlos syndrome (HSD/hEDS) [<span>1, 2</span>].</p><p>They commented on the high frequency of food intolerance in the HSD/hEDS population resulting in a high prevalence of enteral and parenteral feeding, and the possible role of enteric dysmotility regarding this problem. Enteric dysmotility is often thought to be the underlying cause of food intolerance. However, in our study, enteric dysmotility was present less often (but not entirely absent) in the HSD/hEDS group with gastrointestinal symptoms compared to the control group despite the greater need for enteral/parenteral nutrition in the HSD/hEDS group.</p><p>Regarding the duration of antroduodenal manometry (ADM) protocols, we also see the added value of 24-h recordings. However, given the invasive nature and feasibility of 24-h measurements, we also see major challenges. Furthermore, two recent studies showed that shorter ADM studies of 4 or 7.5 h are reliable for evaluation of enteric motility [<span>3, 4</span>].</p><p>Our findings suggest that enteric dysmotility is not the main cause for gastrointestinal complaints in the HSD/hEDS population. A broader view on the pathophysiological mechanism underlying gastrointestinal symptoms in HSD/hEDS patients is necessary. Visceral hypersensitivity should be explored further in this context: it is well described in relation to disorders of gut-brain interaction and contributes significantly to symptom generation in response to normal physiological stimuli, such as food [<span>5</span>]. This phenomenon can be translated to patients with HSD/hEDS, who can exhibit characteristics of central sensitisation and enhanced pain perception, possibly linked to autonomic dysfunction [<span>6</span>]. Additionally, dietary habits and psychological comorbidities including disordered eating must be included in this broader framework because psychiatric problems such as eating disorders are not uncommon within the HSD/hEDS population [<span>7, 8</span>].</p><p>In conclusion, we agree that further research is warranted to elucidate the gastrointestinal manifestations of HSD/hEDS, with particular emphasis on food intolerances. However, we advocate for a more comprehensive approach that addresses gastric and enteric dysmotility but also encompasses factors such as visceral hypersensitivity, autonomic dysfunction, dietary habits and psychological factors.</p><p><b>Kim W. E. Sweerts:</b> writing – original draft. <b>Zlatan Mujagic:</b> writing – review and editing. <b>Daniel Keszthelyi:</b> writing – review and editing. <b>José M. Conchillo:</b> writing – review and editing.</p><p>This article is linked to Sweerts et al. paper. To view this article, visit, https://doi.org/10.1111/apt.18471 and https://doi.org/10.1111/apt.70142.</p>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"61 11","pages":"1845-1846"},"PeriodicalIF":6.6,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.70157","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143915078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD-An Umbrella Review.","authors":"Olga M Nardone,Nurulamin M Noor,Aniruddh Prabhu,Alessandra Lim,Anirudh Krishnakumar,Abdulaziz Alajmi,Yuhong Yuan,Vipul Jairath,Maria Manuela Estevinho,Virginia Solitano","doi":"10.1111/apt.70181","DOIUrl":"https://doi.org/10.1111/apt.70181","url":null,"abstract":"BACKGROUNDExtraintestinal manifestations (EIMs) occur commonly in patients with inflammatory bowel disease (IBD), affecting joints, skin, eyes and other organs, and contributing to morbidity and long-term disability.AIMSTo synthesise evidence from systematic reviews (SRs) on the effectiveness and safety of medical treatments for IBD EIMs in IBD of joints, skin and eyes.METHODSFor this umbrella review, we searched three databases for relevant SRs published until May 30, 2024. Two independent reviewers performed screening, data extraction and quality appraisal (AMSTAR-2).RESULTSTen, 12 and six SRs, respectively, provided data on medical therapies for articular, dermatological and ocular manifestations. Anti-TNF therapy showed high response rates for axial (59.1%-61.8%) and peripheral arthritis (73.4%-81.2%). The lowest improvement was in patients treated with vedolizumab for joint manifestations. Ustekinumab was effective for arthralgia and psoriatic arthritis, but not for axial spondylarthritis. High heterogeneity of response was reported for anti-TNF, vedolizumab, ustekinumab and tofacitinib (21%-100%) depending on the dermatological manifestation. No SRs evaluated IL-23 p40 antagonists or other oral small molecules. The incidence of new ocular EIMs was 1% for vedolizumab and ustekinumab. Anti-TNF agents were effective for most ocular EIM cases. Ustekinumab improved ocular symptoms in 55%-59%. Safety data were limited, with evidence certainty ranging from moderate to low.CONCLUSIONSEvidence for medical therapies for joint, skin and eye EIMs in IBD is heterogeneous and of low quality. Further research is needed, including a multidisciplinary approach and novel and practical methods for endpoint evaluation.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"2 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143915186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse. Authors' Reply","authors":"Shinichiro Shinzaki, Yasuhiro Takagi, Toshiyuki Sato","doi":"10.1111/apt.70180","DOIUrl":"https://doi.org/10.1111/apt.70180","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"99 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143910149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse","authors":"Mark A. Ainsworth, Camilla Frimor","doi":"10.1111/apt.70160","DOIUrl":"https://doi.org/10.1111/apt.70160","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"1 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143909863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Trial: Effect of a 28‐Day Low FODMAP Diet on Gastrointestinal Symptoms Associated With Endometriosis (EndoFOD)—A Randomised, Controlled Crossover Feeding Study","authors":"Jane E. Varney, Daniel So, Peter R. Gibson, Dakota Rhys‐Jones, Yuet Sang Jimmy Lee, Jane Fisher, Judith S. Moore, Roni Ratner, Mark Morrison, Rebecca E. Burgell, Jane G. Muir","doi":"10.1111/apt.70161","DOIUrl":"https://doi.org/10.1111/apt.70161","url":null,"abstract":"BackgroundGastrointestinal symptoms affect most women with endometriosis, but therapeutic interventions are poorly defined.AimsTo compare the effects of a 28‐day low fermentable oligo‐, di‐ and mono‐saccharides and polyols (FODMAP) or control diet on gastrointestinal symptom severity in individuals with endometriosis and poorly controlled gastrointestinal symptoms.MethodIn this single‐blinded randomised, controlled cross‐over feeding trial, we randomised women aged ≥ 18 years to 28 days of either a low FODMAP (&lt; 5 g/day FODMAPs) or control diet (20 g/day FODMAPs), both modelled on Australian Dietary Guidelines, before a ≥ 28‐day washout and crossover to the alternate diet. The primary outcome was the proportion of responders defined according to the response in overall gastrointestinal symptoms on a 100‐mm visual analogue scale. Secondary outcomes included gastrointestinal symptoms, quality of life and psychological status.ResultsOf 35 women randomised (mean age 31; 95% confidence interval 29, 33 years), 21 (60%) responded to the low FODMAP diet compared with 9 (26%) to the control diet (<jats:italic>p</jats:italic> = 0.008). In the 4th week of the dietary intervention, overall symptom scores were 35 (21, 42) mm on the low FODMAP diet and 58 (55, 65) mm on the control diet (<jats:italic>p</jats:italic> &lt; 0.001). Abdominal pain, bloating, stool form and quality of life for both gastrointestinal and endometriosis‐associated scales were significantly better for the low FODMAP diet compared with the control diet, but not overall for perceived stress, anxiety or depression.ConclusionsThe low FODMAP diet ameliorates gastrointestinal symptoms related to endometriosis and improves quality of life. Confirmation of these findings in a real‐world setting is required.Trial RegistrationThe trial is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12621000153819).","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"8 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tenofovir Alafenamide Therapy Throughout Pregnancy in Mothers With Hepatitis B","authors":"Xingfei Pan, Liyang Zhou, Jing Hu, Panpan Zhai, Xueting Ou, Fang He, Calvin Q. Pan","doi":"10.1111/apt.70173","DOIUrl":"https://doi.org/10.1111/apt.70173","url":null,"abstract":"BackgroundMothers with chronic hepatitis B and advanced fibrosis may require antiviral therapy throughout pregnancy. Current guidelines recommend tenofovir disoproxil fumarate (TDF), which is unsuitable for mothers at risk of renal dysfunction or decreased bone mineral density.AimsThis study aimed to evaluate the safety of tenofovir alafenamide (TAF) therapy during pregnancy.MethodsMothers with chronic hepatitis B treated with TAF or no therapy were retrospectively enrolled and categorised into three groups: (A) TAF‐first trimester, (B) TAF‐late trimester and (C) no treatment. Propensity score matching was applied to create comparable groups. Primary assessments included serious adverse events up to postpartum week 28, while secondary assessments examined predictors of such events and vertical transmission rates.ResultsAmong 284 mothers, 160 were selected. No significant differences were observed in foetal loss, low birth weight, preterm delivery or congenital abnormalities between groups A and B, or between groups A and C. Other adverse events were similar across groups, except for a higher incidence of gestational diabetes in the TAF‐first trimester group. In vitro fertilisation was identified as the sole predictor of serious events. No infants were reported with hepatitis B virus infection at 28 weeks postpartum.ConclusionsThis study suggests that TAF treatment throughout pregnancy is safe for mothers with chronic hepatitis B and their infants. TAF therapy represents a viable treatment option for these mothers.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"74 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU","authors":"María José Casanova, Cristina Rubín de Célix, Sabino Riestra, Alfredo J. Lucendo, José Manuel Benítez, Mercè Navarro-Llavat, Jesús Barrio, Víctor J. Morales-Alvarado, Montserrat Rivero, David Busquets, Eduardo Leo-Carnerero, Oscar Nantes-Castillejo, Pablo Navarro, Manuel Van Domselaar, Ana Gutiérrez-Casbas, Inmaculada Alonso-Abreu, Manuel Barreiro-de Acosta, Luis Fernández-Salazar, Marisa Iborra, María Dolores Martín-Arranz, Natalia García-Morales, Jordi Guardiola, Abdel Bouhmidi-Assakali, María Esteve, Carmen Muñoz-Villafranca, Iago Rodríguez-Lago, Daniel Ceballos, Iván Guerra, Miriam Mañosa, Ignacio Marín-Jiménez, Isabel Vera-Mendoza, Ana Garre, María Chaparro, Javier P. Gisbert","doi":"10.1111/apt.70172","DOIUrl":"https://doi.org/10.1111/apt.70172","url":null,"abstract":"The EXIT trial found no difference in sustained remission at 12 months between inflammatory bowel disease (IBD) patients in remission who withdrew anti-TNF therapy [withdrawal arm (WA)] and those who maintained treatment [maintenance arm (MA)].","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"12 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143909801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}